Rapport Therapeutics, Inc.

Historical 13F Holders

Symbol
RAPP
CUSIP
75383L102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 75383L102 since 12/18/2024, newest first.

Filer % of Class Filed
Third Rock Ventures V, L.P. 13G/A Amendment 1
13.1% 8/14/2026
Event 6/30/2026
Cormorant Asset Management, LP 13G/A Amendment 5
5.6% 8/14/2026
Event 6/30/2026
Capital International Investors 13G/A Amendment 1 6.1% 8/12/2026
Event 6/30/2026
Cormorant Asset Management, LP 13G/A Amendment 4
6.2% 5/15/2026
Event 3/31/2026
Cormorant Asset Management, LP 13G/A Amendment 3
6.4% 2/17/2026
Event 12/31/2025
BlackRock, Inc. 13G 5.0% 1/21/2026
Event 12/31/2025
Cormorant Asset Management, LP 13G/A Amendment 2
6.7% 11/14/2025
Event 9/30/2025
Johnson & Johnson 13G/A Amendment 1
4.9% 10/22/2025
Event 9/30/2025
Sofinnova Venture Partners XI, L.P. 13D/A Amendment 1
4.2% 9/18/2025
Event 9/11/2025
Third Rock Ventures V, L.P. 13G
19.5% 2/13/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 4 730 $24.5 k
2026 Q2 165 52.6 M $2.16 B
2026 Q1 150 52.5 M $1.64 B
2025 Q4 148 51.3 M $1.56 B
2025 Q3 134 49.3 M $1.46 B
2025 Q2 84 38.5 M $438 M
2025 Q1 80 38.1 M $382 M
2024 Q4 71 36.6 M $649 M
2024 Q3 57 28.4 M $582 M
2024 Q2 36 25.6 M $593 M